Akebia Ther Stock Fundamentals
| AKBA Stock | USD 2.26 0.57 33.73% |
Akebia Ther fundamentals help investors to digest information that contributes to Akebia Ther's financial success or failures. It also enables traders to predict the movement of Akebia Stock. The fundamental analysis module provides a way to measure Akebia Ther's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Akebia Ther stock.
Akebia |
Akebia Ther Company Current Valuation Analysis
Akebia Ther's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Akebia Ther Current Valuation | 364.5 M |
Most of Akebia Ther's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Akebia Ther is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Akebia Ther has a Current Valuation of 364.5 M. This is 97.46% lower than that of the Biotechnology sector and 92.15% lower than that of the Health Care industry. The current valuation for all United States stocks is 97.81% higher than that of the company.
Akebia Ther Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Akebia Ther's current stock value. Our valuation model uses many indicators to compare Akebia Ther value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Akebia Ther competition to find correlations between indicators driving Akebia Ther's intrinsic value. More Info.Akebia Ther is rated below average in return on equity category among its peers. It is rated second in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Akebia Ther's earnings, one of the primary drivers of an investment's value.Akebia Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Akebia Ther's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Akebia Ther could also be used in its relative valuation, which is a method of valuing Akebia Ther by comparing valuation metrics of similar companies.Akebia Ther is currently under evaluation in current valuation category among its peers.
Akebia Fundamentals
| Return On Equity | -5.53 | ||||
| Return On Asset | -0.0937 | ||||
| Profit Margin | (0.27) % | ||||
| Operating Margin | (0.33) % | ||||
| Current Valuation | 364.5 M | ||||
| Shares Outstanding | 218.18 M | ||||
| Shares Owned By Insiders | 4.81 % | ||||
| Shares Owned By Institutions | 31.29 % | ||||
| Number Of Shares Shorted | 14.98 M | ||||
| Price To Earning | (4.84) X | ||||
| Price To Book | 4.12 X | ||||
| Price To Sales | 2.17 X | ||||
| Revenue | 194.62 M | ||||
| Gross Profit | 142.93 M | ||||
| EBITDA | (6.87 M) | ||||
| Net Income | (51.92 M) | ||||
| Cash And Equivalents | 143.89 M | ||||
| Cash Per Share | 0.78 X | ||||
| Total Debt | 104.18 M | ||||
| Debt To Equity | 2.15 % | ||||
| Current Ratio | 1.30 X | ||||
| Book Value Per Share | (0.24) X | ||||
| Cash Flow From Operations | (23.38 M) | ||||
| Short Ratio | 7.64 X | ||||
| Earnings Per Share | (0.22) X | ||||
| Target Price | 7.83 | ||||
| Number Of Employees | 167 | ||||
| Beta | 0.94 | ||||
| Market Capitalization | 368.73 M | ||||
| Total Asset | 241.7 M | ||||
| Retained Earnings | (1.61 B) | ||||
| Working Capital | 18.28 M | ||||
| Current Asset | 141.02 M | ||||
| Current Liabilities | 11.87 M | ||||
| Net Asset | 241.7 M |
About Akebia Ther Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Akebia Ther's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Akebia Ther using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Akebia Ther based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Akebia Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 426 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Akebia Ther offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Akebia Ther's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Akebia Ther Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Akebia Ther Stock:Check out Akebia Ther Piotroski F Score and Akebia Ther Altman Z Score analysis. For information on how to trade Akebia Stock refer to our How to Trade Akebia Stock guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akebia Ther. If investors know Akebia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akebia Ther listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Akebia Ther is measured differently than its book value, which is the value of Akebia that is recorded on the company's balance sheet. Investors also form their own opinion of Akebia Ther's value that differs from its market value or its book value, called intrinsic value, which is Akebia Ther's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akebia Ther's market value can be influenced by many factors that don't directly affect Akebia Ther's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akebia Ther's value and its price as these two are different measures arrived at by different means. Investors typically determine if Akebia Ther is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akebia Ther's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.